NanoViricides Inc (AMEX: NNVC)’s stock price has gone decline by -5.37 in comparison to its previous close of 1.49, however, the company has experienced a -0.70% decrease in its stock price over the last five trading days. proactiveinvestors.com reported 2024-09-30 that NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as COVID-19, RSV, and influenza.
Is It Worth Investing in NanoViricides Inc (AMEX: NNVC) Right Now?
The 36-month beta value for NNVC is at 0.96. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NNVC is 13.97M, and currently, shorts hold a 3.21% of that float. The average trading volume for NNVC on October 04, 2024 was 245.77K shares.
NNVC’s Market Performance
The stock of NanoViricides Inc (NNVC) has seen a -0.70% decrease in the past week, with a -18.97% drop in the past month, and a -19.43% fall in the past quarter. The volatility ratio for the week is 7.69%, and the volatility levels for the past 30 days are at 8.29% for NNVC. The simple moving average for the past 20 days is -9.32% for NNVC’s stock, with a -10.36% simple moving average for the past 200 days.
Analysts’ Opinion of NNVC
Many brokerage firms have already submitted their reports for NNVC stocks, with Midtown Partners repeating the rating for NNVC by listing it as a “Strong Buy.” The predicted price for NNVC in the upcoming period, according to Midtown Partners is $5.30 based on the research report published on February 11, 2015 of the previous year 2015.
NNVC Trading at -22.52% from the 50-Day Moving Average
After a stumble in the market that brought NNVC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.72% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 7.69%, as shares sank -21.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.37% lower at present.
During the last 5 trading sessions, NNVC fell by -0.70%, which changed the moving average for the period of 200-days by +29.36% in comparison to the 20-day moving average, which settled at $1.5360. In addition, NanoViricides Inc saw 38.24% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NNVC
The total capital return value is set at -0.74. Equity return is now at value -63.00, with -55.81 for asset returns.
Currently, EBITDA for the company is -8.52 million with net debt to EBITDA at 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.
Conclusion
In conclusion, NanoViricides Inc (NNVC) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
